Jubilant Ingrevia (JUBLINGREA) Q1 24/25 earnings summary

Executive summary

• Achieved healthy sequential performance in Q1 FY25, driven by specialty chemicals and cost initiatives over the past three quarters.

• Strong demand in pharmaceutical and nutrition segments, with significant traction in regulated markets (North America, Europe, Japan).

• USFDA inspection at Bharuch facility completed with zero 483 observations, supporting growth in regulated and nutraceutical markets.

• Gained momentum in CDMO business, with new orders delivered and advanced discussions ongoing in pharma, agro, and semiconductor sectors.

• Focus remains on customer-centricity, ramping up new plants, cost control, and sustainability initiatives.

Financial highlights

• Q1 FY25 consolidated revenue was ₹102,434 lakhs, down from ₹107,502 lakhs in Q1 FY24, mainly due to lower chemical intermediate segment revenue.

• EBITDA for the quarter stood at ₹11,900 lakhs, up 18% sequentially but down 5% year-over-year; margin improved to 12%.

• Net profit for Q1 FY25 was ₹4,874 lakhs, up 67% sequentially but down 15% year-over-year.

• Net debt as of June 30, 2024, was ₹67,700 lakhs, with a net debt to equity ratio of 1.5x (TTM EBITDA basis).

• Capital expenditure for the quarter was ₹11,600 lakhs, funded primarily through internal accruals.

Outlook and guidance

• Expect improvements across all business segments in FY25 over FY24.

• Specialty chemicals targeted to maintain 20%+ EBITDA margins, with aspirations to reach 23-25% as product mix improves.

• Nutrition margins expected to rise to 17-18%+ with new food and cosmetic grade products; steady state for feed segment at 12-13%.

• CDMO business expected to grow 25-30% YoY, with pharma steady at 20-25% and agro growth lumpy but significant.

• Long-term vision: triple revenue and quadruple EBITDA in five years, aiming for 20%+ company-level EBITDA margin.